Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.78 Increased by +220.00% | 0.81 Decreased by -3.70% |
| May 11, 23 | -0.73 Decreased by -30.36% | -0.66 Decreased by -10.61% |
| Mar 23, 23 | -0.53 Decreased by -17.78% | -0.67 Increased by +20.90% |
| Nov 10, 22 | -0.53 Decreased by -26.19% | -0.63 Increased by +15.87% |
| Aug 15, 22 | -0.65 Decreased by -71.05% | -0.64 Decreased by -1.56% |
| May 12, 22 | -0.56 Decreased by -124.00% | -0.55 Decreased by -1.82% |
| Mar 24, 22 | -0.45 Decreased by -87.50% | -0.54 Increased by +16.67% |
| Nov 10, 21 | -0.42 Increased by +62.50% | -0.50 Increased by +16.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.60 M Decreased by -24.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -25.87 M Decreased by -39.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -25.70 M Decreased by -57.30% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -16.25 M Decreased by -3.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -23.84 M Decreased by -70.62% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -18.57 M Decreased by -109.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -16.34 M Decreased by -112.14% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -15.67 M Decreased by -85.36% | Decreased by N/A% Decreased by N/A% |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.